Stay updated with breaking news from Valency Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JANUARY - MARCH IN SUMMARY Net sales for the period amounted to KSEK 1,794 (-).Result for the period amounted to KSEK -27,582 (-41,571).Earnings and diluted earnings per share totaled SEK -0.14 (-0.25).Immunicum
Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, announced the appointment of Leopold Bertea
COMBINATION OF CANCER RELAPSE VACCINE CANDIDATE WITH 5'-AZACITIDINE AND VENETOCLAX SHOWS SUPERIOR TUMOR REDUCTION IN AN AML MODEL Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical
Immunicum AB , a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following upcoming... | April 19, 2022
Investegate announcements from Immunicum AB, Immunicum AB: Immunicum AB (publ) Publishes the Annual Report for 2021